Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility
| Brand name | CLEVIPREX |
| Generic name | CLEVIPIDINE |
| Active ingredient(s) | CLEVIDIPINE |
| Distributed by / for | Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria |
| NDC | 10122-611-10 |
| Full product label | CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10. |
| Recalling firm | Chiesi USA, Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 44280 vials |
| Recall initiated | 2026-07-06 |
| Report date | 2026-07-22 |
| Recall completed | — |
| Recall number | D-0689-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Cary NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗